相关实验视频
Updated: Jan 14, 2026
07:39
Mouse In Vivo Placental Targeted CRISPR Manipulation
Published on: April 14, 2023
3.5K
在先天性孤立生长激素缺乏症中,IGF-I的生物可用性
Viviane C Campos1, Manuel H Aguiar Oliveira1, Martin Bidlingmaier2
1Health Sciences Graduate Program, Federal University of Sergipe, Aracaju, Brazil.
European journal of endocrinology
|January 13, 2026
概括
在Itabaianinha队列中,先天性孤立生长激素缺乏症 (GHD) 与通过ISPa轴改变IGF-I生物可用性有关. 这导致PAPP-A2活性增加和PAPP-A功能减少,尽管正常寿命.
科学领域:
- 内分泌学 在内分泌学.
- 遗传学 遗传学是一种遗传学.
- 生物化学 生物化学
背景情况:
- 伊塔拜安尼尼哈队列由于GHRH受体 (GHRH-R) 突变而表现出先天性孤立GH缺乏症 (GHD),表现为严重的矮身,但寿命正常.
- 胰岛素样生长因子-I (IGF-I) 的生物可用性由IGFBP 4-STC2-PAPP-A轴 (ISPa) 调节,涉及蛋白质分解裂变来激活受体.
研究的目的:
- 在由GHRH-R突变引起的先天隔离GH缺乏症 (GHD) 患者中研究IGFBP 4-STC2-PAPP-A轴 (ISPa).
- 评估IGF-I生物可用性调节在终身GHD的背景下发生的变化.
主要方法:
- 在GHD受试者 (同卵性GHRH-R突变),异卵性受试者 (HTZ) 和同卵性野生类型对照者 (HMZ) 中评估ISPa参数.
- 测量的生物化学参数包括GH,IGF-I,IGF-II,自由的IGF-I,IGFBP3,STC2,PAPP-A,PAPP-A2和完整的IGFBP 4.
主要成果:
- 与对照人群相比,GHD患者的GH,IGF-I,IGF-II,自由IGF-I和IGFBP3显著降低.
- 虽然STC2,PAPP-A和PAPP-A-STC2复合物的水平相似,但GHD个体具有更高的PAPP-A2和完整的IGFBP 4.
- IGF-I和IGFBP 3与IGF-II正相关,而完整的IGFBP 4和PAPP-A2与IGF-I和IGF-II相反相关.
结论:
- 研究结果表明,IGF-I在终身GHD中的生物可用性通过ISPa轴失调.
- 增加的PAPP-A2活性和减少的PAPP-A酶功能,以及减少的STC2封存,似乎是关键机制.
关键词:
发生GHRH受体突变4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4 IGFBP 4孤立生长激素缺乏症 孤立生长激素缺乏症伊塔巴伊亚尼尼尼哈队伍这就是PAPP-A.
相关概念视频
01:13Bioavailability: Overview
4.1K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
4.1K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
189
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
189